Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
AUTL Autolus Therapeutics plc
- Stocks
- Healthcare
- NASDAQ: AUTL
Price (delayed)
$1.22
Market cap
$324.69M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.88
Enterprise value
$543.39M
autolus is a private biopharmaceutical company, focused on the development and commercialisation of engineered t-cell immunotherapy products with extreme efficacy in the treatment of life-threatening cancers. we are building a
Highlights
The EPS has grown by 27% year-on-year but it has declined by 2.3% since the previous quarter
Autolus Therapeutics's quick ratio has shrunk by 54% YoY and by 18% QoQ
Autolus Therapeutics's equity has decreased by 36% YoY and by 13% QoQ
Key stats
What are the main financial stats of AUTL
Market
Valuations
Earnings
Shares outstanding
266.14M
Market cap
$324.69M
Enterprise value
$543.39M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.87
Price to sales (P/S)
36.03
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
60.3
Revenue
$9.01M
Gross profit
-$20.33M
Operating income
-$267.69M
Net income
-$238.13M
EBIT
-$234.21M
EBITDA
-$221.38M
Free cash flow
-$271.11M
Per share
Balance sheet
Liquidity
EPS
-$0.88
EPS diluted
-$0.88
Free cash flow per share
-$1.02
Book value per share
$1.39
Revenue per share
$0.03
TBVPS
$2.76
Total assets
$746.34M
Total liabilities
$375.23M
Debt
$315.95M
Equity
$371.11M
Working capital
$549.16M
Debt to equity
0.85
Current ratio
9.24
Quick ratio
7.99
Net debt/EBITDA
-0.99
Margins
Efficiency
Dividend
EBITDA margin
-2,456.8%
Gross margin
-225.6%
Net margin
-2,642.7%
Operating margin
-2,970.7%
Return on assets
-29.7%
Return on equity
-52.8%
Return on invested capital
-37.8%
Return on capital employed
-34.5%
Return on sales
-2,599.1%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
AUTL stock price
How has the Autolus Therapeutics stock price performed over time
Intraday
-3.94%
1 week
-0.81%
1 month
-8.96%
1 year
-68.96%
YTD
-48.09%
QTD
-21.29%
Financial performance
How have Autolus Therapeutics's revenue and profit performed over time
Revenue
$9.01M
Gross profit
-$20.33M
Operating income
-$267.69M
Net income
-$238.13M
Gross margin
-225.6%
Net margin
-2,642.7%
AUTL's operating margin has dropped by 74% year-on-year and by 25% since the previous quarter
Autolus Therapeutics's operating income has decreased by 49% YoY and by 11% QoQ
AUTL's net margin is down by 25% year-on-year and by 21% since the previous quarter
Autolus Therapeutics's revenue has decreased by 14% YoY and by 11% from the previous quarter
Price vs fundamentals
How does AUTL's price correlate with its fundamentals
Growth
What is Autolus Therapeutics's growth rate over time
Valuation
What is Autolus Therapeutics stock price valuation
P/E
N/A
P/B
0.87
P/S
36.03
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
60.3
The EPS has grown by 27% year-on-year but it has declined by 2.3% since the previous quarter
AUTL's price to book (P/B) is 59% lower than its 5-year quarterly average of 2.1 and 46% lower than its last 4 quarters average of 1.6
Autolus Therapeutics's equity has decreased by 36% YoY and by 13% QoQ
AUTL's price to sales (P/S) is 82% lower than its 5-year quarterly average of 200.4 and 50% lower than its last 4 quarters average of 72.2
Autolus Therapeutics's revenue has decreased by 14% YoY and by 11% from the previous quarter
Efficiency
How efficient is Autolus Therapeutics business performance
The return on sales has dropped by 69% year-on-year and by 25% since the previous quarter
The return on equity has grown by 34% year-on-year but it has declined by 21% since the previous quarter
Autolus Therapeutics's return on assets has increased by 28% YoY but it has decreased by 13% QoQ
Autolus Therapeutics's ROIC has increased by 25% YoY and by 11% from the previous quarter
Dividends
What is AUTL's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for AUTL.
Financial health
How did Autolus Therapeutics financials performed over time
The company's total assets is 99% higher than its total liabilities
Autolus Therapeutics's quick ratio has shrunk by 54% YoY and by 18% QoQ
AUTL's current ratio is down by 49% year-on-year and by 15% since the previous quarter
AUTL's debt is 15% smaller than its equity
The company's debt to equity has surged by 77% YoY and by 21% QoQ
Autolus Therapeutics's equity has decreased by 36% YoY and by 13% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.